eagledon pharmaceutical-最新凯时注册

web disclaimer 

notice: online access to prospectus 

by accessing the electronic prospectus, youagree to and acknowledge reading these terms. if you would like us to send youa copy of the prospectus and an application form, please contact theinformation line by telephone on 1300 737 760 (within australia) or 61 2 92909600 (outside australia) during the period in which the offer for sharesremains open and a copy will be sent to you free of charge.

1. prospectus 

eagle health holdings limited (acn 616 382515) (company) lodged a second replacement prospectus dated 24 april 2017(prospectus) with the australian securities and investments commission (asic)to raise up to $30 million by issuing up to 75 million fully paid ordinaryshares (shares) at $0.40 per share (offer). the offer will only be made pursuantto the prospectus and full details of the offer are set out in theprospectus. 

no person is authorised to give anyinformation or to make any representation in relation to the offer which is notcontained in the prospectus and any such information may not be relied upon ashaving been authorised by the company. 

2. important information 

this notice does not form part of theprospectus. you must read it before you attempt to access the electronicversion of the prospectus on this website and indicate your agreement orotherwise at the bottom of this notice.

the prospectus is an important documentthat should be read in its entirety. potential investors should read the entireprospectus and, in particular, in considering the prospects for the company, investorsshould consider the risk factors that could affect the performance of thecompany. 

investors should carefully consider thesefactors in light of their personal circumstances (including financial andtaxation issues) and seek professional advice from a licensed investmentadviser. neither asic nor asx limited takes any responsibility for the contentsof the prospectus or the investment to which it relates. the prospectus expireson 23 may 2018. no shares will be issued on the basis of the prospectus afterthat expiry date.

3. foreign jurisdictions 

this prospectus does not, and is notintended to, constitute an offer in any place or jurisdiction in which, or toany person to whom, it would not be lawful to make such an offer or to issuethe prospectus. the distribution of the prospectus in jurisdictions outsideaustralia may be restricted by law and persons who come into possession of theprospectus should seek advice on and observe any such restrictions includinggovernment or other consents and formalities. any failure to comply with suchrestrictions may constitute a violation of applicable securities laws.  itis the responsibility of any applicant outside australia to ensure compliancewith all laws of any country relevant to their application.

no action has been taken to register orqualify the shares, or otherwise to permit a public offering of the shares, inany jurisdiction outside australia and the offer is not an offer or invitationin any jurisdiction where, or to any person whom, such an offer or invitationwould be unlawful. in particular, the shares have not been, and will not be,registered under the united states securities act of 1933, as amended (ussecurities act) and may not be offered or sold in the united states except intransaction exempt from, or not subject to, registration under the ussecurities act and applicable us state securities laws. 

by proceeding, you confirm that you are aresident of australia accessing this website from within australia and yourepresent, warrant and agree that you are not in the united states or any otherjurisdiction outside australia. 

4. application for shares 

after the expiry of the exposure period,the electronic version of the prospectus will include an application form atthe end of the document. applications for shares may only be made by completingand lodging the application form attached to or accompanied by a paper copy ofthe prospectus in accordance with the directions specified in the prospectus. 

the corporations act prohibits any personfrom distributing to any other person an application form unless it is attachedto a paper copy of the prospectus or accompanies a complete and unalteredversion of the electronic prospectus.  the company will not accept acompleted application form if it has reason to believe that the applicant hasnot received a complete and unaltered copy of the prospectus.  any personmay obtain a paper copy of the prospectus by contacting the company prior tothe closing date for the offer. 

5. acknowledgement 

the information on this website is providedfor informational purposes only and subject to change without notice. nothingcontained on this website or in the prospectus constitutes investment, legal,business, taxation or other advice, nor is it to be relied on in making aninvestment in the shares. the information on this website and in the prospectusdoes not take into account your investment objectives, financial situation orparticular needs.  if you have any doubts or queries in relation to the prospectus,you should consult your legal, financial or other professional adviser. 

subject to the terms contained in thisnotice, an electronic copy of the prospectus may be viewed or downloaded. youshould ensure that any copy you view or print is complete. 

i confirm have read and understood thisnotice and agree to the terms and conditions above.